Search Results

You are looking at 1 - 4 of 4 items for :

Clear All
Open access

Primary prevention strategy for cardiovascular disease in Lithuania

(“A Funding Programme for the Screening and Preventive Management of the High Cardiovascular Risk Individuals” – main results: 2006–2017 years)

Aleksandras Laucevičius, Egidija Rinkūnienė, Ligita Ryliškytė, Vytautas Kasiulevičius, Dalius Jatužis, Žaneta Petrulionienė, Jolita Badarienė, Rokas Navickas, Agnė Jucevičienė, Sandra Kutkienė, Svetlana Solovjova, Viktorija Andrejevaitė, Ingrida Lisauskienė, Jūratė Zupkauskienė, Roma Puronaite, Romualdas Gurevičius and Jurgita Mikolaitytė

References [1] Health Information Centre, Institute of Hygiene, Ministry of Health of The Republic of Lithuania, Causes of death 2017, Vilnius 2018. http://www.hi.lt/uploads/pdf/leidiniai/Statistikos/Mirties_priezastys/MPR_2017_isankstiniai.pdf . [2] WHO HFA Mortality database, 2009. [3] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on

Open access

Seminars in Cardiovascular Medicine

The Journal of Lithuanian Heart Association

Open access

Ieva Slivovskaja, Jurgita Buzinskaitė, Ligita Ryliškytė, Jūratė Balsytė, Rokas Navickas, Roma Puronaitė, Agnė Jucevičienė, Alvydas Juocevičius and Aleksandras Laucevičius

. Prev Med 1997;26(6):883–92. [4] Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380(9838):219–29. [5] Laucevičius A, Rinkūnien ˙e E, Skujait ˙e A, Petrulionien ˙e Ž, Puronait ˙e R, Dženkevičiūt ˙e V, et al. Prevalence of cardiovascular risk factors in Lithuanian middle-aged subjects participating in the primary prevention program, analysis of the period 2009–2012. Blood Press 2015;24:41–7. [6

Open access

Jonas Černeckis, Austėja Samuolytė, Greta Baltušytė, Rugilė Ivanickaitė and Kristijonas Puteikis

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are authorized for the relief of pain and inflammation in a wide range of conditions including the discomfort associated with headaches, osteoarthritis, rheumatoid arthritis, and menstrual pain and are available by prescription or over-the-counter (OTC). We reviewed common adverse effects of NSAIDs (especially those related to cardiovascular [CV] system) along with NICE (National Institute for Health and Care Excellence), EMA (European Medicines Agency), and the FDA (U.S. Food and Drug Administration) guidelines for safe and effective use of particular NSAIDs. Furthermore, we examined the NSAIDs market in Lithuania in a period between June 2016 and May 2017 and discussed how well recommendations mentioned above were followed. We emphasized that there was a high percentage of diclofenac prescribed in Lithuania while international guidelines encourage prescribing ibuprofen or naproxen for their relatively lower CV risk. Reviewing past trials, we observed that despite existing guidelines no single NSAID could be considered to be the safest one due to a lack of superiority trials